allowed to make a brief oral presentation at the conclusion of the meeting, if time permits, and at the discretion of the Chairperson.

Individuals wishing to provide only written statements should send three (3) typewritten copies of their comments, including a brief description of their organization, to the above address no later than 4 pm EDT on October 13. Statements submitted after that date will be accepted. They may not, however, be made available to the Area Review Panel prior to the meeting, though they will be provided subsequently as written testimony.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Dr. Mathieson in advance of the meeting.

Dated: September 29, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95–24814 Filed 10–4–95; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Allergy and Infectious Diseases Special Emphasis Panel (SEP) meetings:

Name of SEP: Central Immunology Lab for AIDS Vaccine Clinical Trials.
Date: October 20, 1995.
Time: 11:00 a.m.
Place: Solar Bldg., Room 1A3, 6003 Executive Blvd., Bethesda, MD 20892.
Contact Person: Dr. Dianne E. Tingley, Scientific Review Admin., Solar Bldg., Room 4C07, 6003 Executive Boulevard, Bethesda, MD 20892, (301) 496–0818.
Purpose/Agenda: To evaluate contract proposals.

Name of SEP: National Cooperative Drug Groups for the Treatment of HIV Infection.
Date: October 30–31, 1995.
Time: 8:30 a.m.
Place: Holiday Inn Gaithersburg, Washingtonian Room, 2 Montgomery Village Avenue, Gaithersburg, MD 20879, (301) 948–8900.
Contact Person: Dr. Vassil Georgiev, Scientific Review Admin., Solar Bldg., Room 4C04, 6003 Executive Boulevard, Bethesda, MD 20892, (301) 496–8206.
Purpose/Agenda: To evaluate grant applications.

Name of SEP: Research on Hantavirus and Other Emerging Viral Threats.
Date: November 6–8, 1995.
Time: 8:30 a.m.
Place: Bethesda Ramada Hotel, 8400 Wisconsin Avenue, Bethesda, MD 20814, (301) 654–1000.
Contact Person: Christopher Beisel, Scientific Review Admin., Solar Bldg., Room 4C03, 6003 Executive Boulevard, Bethesda, MD 20892, (301) 402–4596.
Purpose/Agenda: To evaluate grant applications.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the application and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 93.855, Immunmology, Allergic and Immunologic Diseases Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: September 29, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95–24813 Filed 10–4–95; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meetings of Subcommittees B, C, and D of the Diabetes and Digestive and Kidney Diseases Special Grants Review Committee

Pursuant to Public Law 92–463, notice is hereby given of meetings of Subcommittees B, C, and D of the National Diabetes and Digestive and Kidney Diseases Special Grants Review Committee, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

These meetings will be open to the public as indicated below to discuss Council decisions on training matters and updates on NIH training policy. Attendance by the public will be limited to space available. Notice of the meeting rooms will be posted in the hotel lobby.

These meetings will be closed to the public as indicated below in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and sec. 10(d) of Public Law 92–463, for the review, discussion, and evaluation of individual research grant applications. Discussion of these applications could reveal confidential trade secrets or commercial property, such as patentable material, and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Mrs. Winnie Martinez, Committee Management Officer, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 31, Room 9A07, Bethesda, Maryland 20892, 301–496–6623, will provide summaries of the meetings and rosters of the committee members upon request. Other information pertaining to the meetings can be obtained from the contact person.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the contact person at least two weeks prior to the meeting date.

Name of Committee: National Diabetes and Digestive and Kidney Diseases, Special Grants Review Committee, Subcommittee B.
Date: October 26–27, 1995.
Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.
Open: October 26, 5:30 p.m.–7 p.m.
Purpose/Agenda: To discuss administrative details.
Closed: October 27, 8 a.m.–adjournment.
Purpose/Agenda: To review and evaluate research grant applications.
Contact Person: Michael W. Edwards, Ph.D., Natcher Building, Room 6AS–37J, National Institutes of Health, Bethesda, Maryland 20892–6600, Phone: 301–594–8892.

Name of Committee: National Diabetes and Digestive and Kidney Diseases, Special Grants Review Committee, Subcommittee C.
Date: October 26–27, 1995.
Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.
Open: October 26, 5:30 p.m.–7 p.m.
Purpose/Agenda: To discuss administrative details.
Closed: October 27, 8 a.m.–adjournment.
Purpose/Agenda: To review and evaluate research grant applications.
Contact Person: Daniel Matsumoto, Ph.D., Natcher Building, Room 6AS–37B, National Institutes of Health, Bethesda, Maryland 20892–6600, Phone: 301–594–8894.

Name of Committee: National Diabetes and Digestive and Kidney Diseases, Special Grants Review Committee, Subcommittee D.
Date: October 26–27, 1995.
Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.
Open: October 26, 5:30 p.m.–7 p.m.
Purpose/Agenda: To discuss administrative details.
Closed: October 27, 8 a.m.–adjournment.
Purpose/Agenda: To review and evaluate research grant applications.
Contact Person: Ann A. Hagan, Ph.D., Natcher Building, Room 6AS–43G, National Institutes of Health, Bethesda, Maryland 20892–6600, Phone: 301–594–8891.

(Catalog of Federal Domestic Assistance Program No. 93.847–849, Diabetes, Endocrine and Metabolic Diseases; Digestive Diseases and Nutrition; and Kidney Diseases, Urology

and Hematology Research, National Institutes of Health)

Dated: September 29, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95–24811 Filed 10–4–95; 8:45 am]

BILLING CODE 4140–01–M

National Institutes of Nursing Research; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

Name of Committee: Nursing Science Review Committee.

Date: October 25–27, 1995.

Time: 8:30 a.m. until adjournment.

Place: Holiday Inn Chevy Chase, Palladian West Conference Room, 5520 Wisconsin Avenue, Bethesda, Maryland 20815.

Contact Person: Dr. Mary Stephens-Frazier, 9000 Rockville Pike, Building 45, Room 3AN.12, Bethesda, Maryland 20892, (301) 594–5971.

Purpose: To review and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in sec. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program No. 93.361, Nursing Research, National Institutes of Health.)

Dated: September 29, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95–24810 Filed 10–4–95; 8:45 am]

BILLING CODE 4140–01–M

National Institute on Deafness and Other Communication Disorders; Notice of Meeting of the Deafness and Other Communication Disorders Programs Advisory Committee

Pursuant to Public Law 92–463, notice is hereby given of a meeting of the Deafness and Other Communication Disorders Programs Advisory Committee.

Date: October 27, 1995.

Place: National Institutes of Health, 9000 Wisconsin Avenue, Building 31C, Conference Room 6, Bethesda MD 20892.

Time: 8 am to 5 pm.

Purpose/Agenda: To hold discussion on Extramural Research programs.

Contact Person: Ralph F. Naunton, M.D., Director, Division of Human Communication, NIH/NIDCD, 6120 Executive Boulevard, MSC 7180, Bethesda MD 20892–7180, 301–496–1804.

The entire meeting will be open to the public, with attendance limited to space available. A summary of the meeting and a roster of the members may be obtained from Dr. Naunton's office. For individuals who plan to attend and need special assistance such as sign language interpretation or other reasonable accommodation, please contact Dr. Naunton prior to the meeting.

(Catalog of Federal Domestic Assistance Program No. 93.173 Biological Research Related to Deafness and Communication Disorders)

Dated: September 29, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95–24812 Filed 10–4–95; 8:45 am]

BILLING CODE 4140–01–M

Public Health Service

Centers for Disease Control and Prevention; Statement of Organization, Functions, and Delegations of Authority

Part H, Chapter HC (Centers for Disease Control and Prevention) of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (45 FR 67772–67776, dated October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as amended most recently at 60 FR 17792–95, dated April 7, 1995) is amended to reflect the establishment of the Office of Women's Health within the Office of the Director, Centers for Disease Control and Prevention (CDC).

Section HC-B, Organization and Functions, is hereby amended as follows:

After the functional statement for the *CDC Washington Office (HCA6),* insert the following:

Office of Women's Health (HCA7). (1) Provides leadership, guidance, and coordination on policy, program planning, and development of CDC activities related to women's health; (2) provides advice to the Director, CDC, on women's health-related issues; (3) establishes short-range and long-range goals and objectives for women's health and facilitates coordination of women's health activities within the Agency that relate to prevention, research, education and training, service delivery, and policy development; (4) identifies needs in women's health that should be addressed by the Agency and provides funding assistance to support projects that address those gaps; (5) advocates for women's health issues and consults with the Public Health Service (PHS), other Federal agencies, State and local health departments, non-governmental organizations, health professionals, consumer organizations, and other individuals and groups, as appropriate, on the policies and activities of the Agency with regard to women; (6) coordinates agency activities on women's health with the PHS Office on Women's Health, and the Director serves as chair of CDC's Women's Health Committee.

Effective Date: September 27, 1995.

Donna E. Shalala,

Secretary.

[FR Doc. 95–24762 Filed 10–4–95; 8:45 am]

BILLING CODE 4160–18–M

Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies and Laboratories That Have Withdrawn From the Program

AGENCY: Substance Abuse and Mental Health Services Administration, HHS (Formerly: National Institute on Drug Abuse, ADAMHA, HHS).

ACTION: Notice.

SUMMARY: The Department of Health and Human Services notifies Federal agencies of the laboratories currently certified to meet standards of Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A similar notice listing all currently certified laboratories will be published during the first week of each month, and updated to include laboratories which subsequently apply for and complete the certification process. If any listed laboratory's certification is totally suspended or revoked, the laboratory will be omitted from updated lists until such time as it is restored to full certification under the Guidelines.

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be identified as such at the end of the current list of certified laboratories, and will be omitted from the monthly listing thereafter.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh, Division of Workplace Programs, Room 13A–54, 5600 Fishers